We’re Making an Impact
Though it is preventable and treatable, malaria kills nearly 660,000 people—most of them children under five in sub-Saharan Africa—each year. To expand access to the best antimalarial treatment, we formed an innovative partnership to develop a semisynthetic form of high-quality, affordable artemisinin that could stabilize the botanically-derived supply. Semisynthetic artemisinin is now in commercial production and has achieved WHO prequalification.
Publications & Resources
OneWorld Health Newsletters will keep you up to date with stories about our work around the globe. Reports from the field. News on the latest clinical trial progress. Fundraising initiatives with our partners. And personal stories about the people we help and how their lives have changed thanks to the medicines we have developed.
OWH fact sheets
OWH Annual Report
» "Microbially Derived Artemisinin: A Biotechnology Solution to the Global Problem of Access to Affordable Antimalarial Drugs", Am. J. Trop. Med. Hygs (2007)
» "Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India",Tropical Medicine and International Health (2010)
» "Visceral leishmaniasis supplement: the economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India",Tropical Medicine and International Health (2010)
» "Developing novel antisecretory drugs to treat infectious diarrhea", Future Science (2011)
» "Implementation Research for the Control of Infectious Diseases of Poverty"
WHO-TDR Research Publication (2011)
» Various PDP Papers
PDP Access Sterring Committee (2010-2011)